![Matthew Sherman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Sherman
Director Técnico/Científico/I+D en
DECIPHERA PHARMACEUTICALS, INC.
.
Perfil
Matthew L.
Sherman is currently the Director at Pulmatrix Operating Co., Inc. He is also the Chief Medical Officer & Executive Vice President at Deciphera Pharmaceuticals, Inc. Additionally, he serves as a Member-Alumni Council at Geisel School of Medicine.
Previously, Dr. Sherman held positions as the Director at NewLink Genetics Corp.
from 2018 to 2020.
He was also the Area Director-Therapeutic Oncology at Wyeth Pharmaceuticals LLC in 2013.
From 2016 to 2020, he served as an Independent Director at Pulmatrix, Inc. Dr. Sherman was an Independent Director at Pieris Pharmaceuticals, Inc. from 2018 to 2024.
He was the Head-Clinical Research & Development at Genetics Institute LLC in 2013.
Prior to that, he was the Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc. from 2015 to 2018.
He also held the position of Chief Medical Officer & Senior Vice President at Synta Pharmaceuticals Corp.
from 2004 to 2006.
Dr. Sherman has an educational background with an undergraduate degree from Massachusetts Institute of Technology and a doctorate from Dartmouth Medical School.
Cargos activos de Matthew Sherman
| Empresas | Cargo | Inicio |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 02/10/2019 |
Pulmatrix Operating Co., Inc.
 Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for respiratory infectious diseases | Director/Miembro de la Junta | - |
Geisel School of Medicine
 Geisel School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Matthew Sherman.
| Empresas | Cargo | Fin |
|---|---|---|
| PIERIS PHARMACEUTICALS | Director/Miembro de la Junta | 13/12/2024 |
| LUMOS PHARMA, INC. | Director/Miembro de la Junta | 18/03/2020 |
| PULMATRIX, INC. | Director/Miembro de la Junta | 31/01/2020 |
| ACCELERON PHARMA INC. | Director Técnico/Científico/I+D | 05/07/2018 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel pharmaceutical products | Director Técnico/Científico/I+D | 01/01/2006 |
Formación de Matthew Sherman.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
66
Relaciones de 1er grado
16
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 16 |
|---|---|
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops, and commercializes novel immunotherapeutic products for treatment of cancer | Health Technology |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for respiratory infectious diseases | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company which develops protein therapeutics for cancer and orphan diseases | Health Technology |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel pharmaceutical products | Health Technology |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets infant pharmaceutical products | Health Technology |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services Provides health care services | Health Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The Marine Biological Laboratory
 The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services Provides research and educational services | Commercial Services |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dartmouth Medical School
 Dartmouth Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pieris Pharmaceuticals, Inc.
 Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Pulmatrix, Inc.
 Pulmatrix, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for pulmonary disease | Health Technology |
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Geisel School of Medicine
Geisel School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Bolsa de valores
- Insiders
- Matthew Sherman
